JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lovenberg, T. W.
Right arrow Articles by Erlander, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lovenberg, T. W.
Right arrow Articles by Erlander, M. G.

Vol. 293, Issue 3, 771-778, June 2000

Cloning of Rat Histamine H3 Receptor Reveals Distinct Species Pharmacological Profiles

Timothy W. Lovenberg, Jayashree Pyati, Hong Chang, Sandy J. Wilson and Mark G. Erlander

R. W. Johnson Pharmaceutical Research Institute, San Diego, California

The recent cloning and characterization of the human histamine H3 receptor cDNA marked a significant step toward a greater understanding of the role of this receptor in the central nervous system. We now report the cloning of the rat histamine H3 receptor cDNA and demonstrate distinct pharmacological species differences. The rat cDNA clone encodes a putative 445-amino acid protein with 93% identity to the human H3 receptor. Northern blot analysis revealed a major single entity of 2.7-kb in length expressed only in brain. Transfection of the rat receptor cDNA into SK-N-MC cells conferred an ability to inhibit forskolin-stimulated cAMP formation in response to histamine and other H3 agonists. N-[3H]methylhistamine saturably bound to transfected cells with high affinity (Kd = 0.8 nM). All agonists tested had low or subnanomolar Ki values similar to that for the human recombinant receptor. The antagonists thioperamide and clobenpropit also bound with high affinity (Ki = 4 and 0.4 nM, respectively). This is in contrast to the antagonist profile obtained for the human recombinant receptor that showed Ki values of 58 and 0.6 nM for thioperamide and clobenpropit, respectively. These data suggest that the low affinity of thioperamide for the human H3 receptor represents a species difference in pharmacology and not a unique pharmacological subtype. It also was found that chloroproxyfan behaved as a full agonist at the rat recombinant receptor. These findings highlight the significance of validating the pharmacology of experimental compounds at both the rat and human H3 receptors.


0022-3565/00/2933-0771$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
E. Davenas, A. Rouleau, S. Morisset, and J. M. Arrang
Autoregulation of McA-RH7777 Hepatoma Cell Proliferation by Histamine H3 Receptors
J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 406 - 413.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
H. L. Haas, O. A. Sergeeva, and O. Selbach
Histamine in the Nervous System
Physiol Rev, July 1, 2008; 88(3): 1183 - 1241.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
S. DeMorrow, H. Francis, and G. Alpini
Biogenic Amine Actions on Cholangiocyte Function
Experimental Biology and Medicine, September 1, 2007; 232(8): 1005 - 1013.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. D. Medhurst, A. R. Atkins, I. J. Beresford, K. Brackenborough, M. A. Briggs, A. R. Calver, J. Cilia, J. E. Cluderay, B. Crook, J. B. Davis, et al.
GSK189254, a Novel H3 Receptor Antagonist That Binds to Histamine H3 Receptors in Alzheimer's Disease Brain and Improves Cognitive Performance in Preclinical Models
J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 1032 - 1045.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
T. A. Esbenshade, G. B. Fox, K. M. Krueger, T. R. Miller, C. H. Kang, L. I. Denny, D. G. Witte, B. B. Yao, L. Pan, J. Wetter, et al.
Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and Selective Histamine H3 Receptor Antagonist with Drug-Like Properties
J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 165 - 175.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
R. L. Thurmond, P. J. Desai, P. J. Dunford, W.-P. Fung-Leung, C. L. Hofstra, W. Jiang, S. Nguyen, J. P. Riley, S. Sun, K. N. Williams, et al.
A Potent and Selective Histamine H4 Receptor Antagonist with Anti-Inflammatory Properties
J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 404 - 413.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
K. Takahashi, S. Tokita, and H. Kotani
Generation and Characterization of Highly Constitutive Active Histamine H3 Receptors
J. Pharmacol. Exp. Ther., October 1, 2003; 307(1): 213 - 218.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
T. A. Esbenshade, K. M. Krueger, T. R. Miller, C. H. Kang, L. I. Denny, D. G. Witte, B. B. Yao, G. B. Fox, R. Faghih, Y. L. Bennani, et al.
Two Novel and Selective Nonimidazole Histamine H3 Receptor Antagonists A-304121 and A-317920: I. In Vitro Pharmacological Effects
J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 887 - 896.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
R. Seifert, K. Wenzel-Seifert, T. Burckstummer, H. H. Pertz, W. Schunack, S. Dove, A. Buschauer, and S. Elz
Multiple Differences in Agonist and Antagonist Pharmacology between Human and Guinea Pig Histamine H1-Receptor
J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 1104 - 1115.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. L. Hofstra, P. J. Desai, R. L. Thurmond, and W.-P. Fung-Leung
Histamine H4 Receptor Mediates Chemotaxis and Calcium Mobilization of Mast Cells
J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 1212 - 1221.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
R. L. Mcleod, C. A. Rizzo, R. E. West Jr., R. Aslanian, K. Mccormick, M. Bryant, Y. Hsieh, W. Korfmacher, G. G. Mingo, L. Varty, et al.

J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 1037 - 1044.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
C. Pillot, J. Ortiz, A. Heron, S. Ridray, J.-C. Schwartz, and J.-M. Arrang
Ciproxifan, a Histamine H3-Receptor Antagonist/Inverse Agonist, Potentiates Neurochemical and Behavioral Effects of Haloperidol in the Rat
J. Neurosci., August 15, 2002; 22(16): 7272 - 7280.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
N. Shin, E. Coates, N. J. Murgolo, K. L. Morse, M. Bayne, C. D. Strader, and F. J. Monsma Jr.
Molecular Modeling and Site-Specific Mutagenesis of the Histamine-Binding Site of the Histamine H4 Receptor
Mol. Pharmacol., July 1, 2002; 62(1): 38 - 47.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. Gomez-Ramirez, J. Ortiz, and I. Blanco
Presynaptic H3 Autoreceptors Modulate Histamine Synthesis through cAMP Pathway
Mol. Pharmacol., January 1, 2002; 61(1): 239 - 245.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K. Wieland, G. Bongers, Y. Yamamoto, T. Hashimoto, A. Yamatodani, W. M. B. P. Menge, H. Timmerman, T. W. Lovenberg, and R. Leurs
Constitutive Activity of Histamine H3 Receptors Stably Expressed in SK-N-MC Cells: Display of Agonism and Inverse Agonism by H3 Antagonists
J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 908 - 914.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. T. Kelley, T. Burckstummer, K. Wenzel-Seifert, S. Dove, A. Buschauer, and R. Seifert
Distinct Interaction of Human and Guinea Pig Histamine H2-Receptor with Guanidine-Type Agonists
Mol. Pharmacol., December 1, 2001; 60(6): 1210 - 1225.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. Liu, S. J. Wilson, C. Kuei, and T. W. Lovenberg
Comparison of Human, Mouse, Rat, and Guinea Pig Histamine H4 Receptors Reveals Substantial Pharmacological Species Variation
J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 121 - 130.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
L. B. Hough
Genomics Meets Histamine Receptors: New Subtypes, New Receptors
Mol. Pharmacol., March 1, 2001; 59(3): 415 - 419.
[Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. B. Silver, C. J. Mackins, N. C. E. Smith, I. L. Koritchneva, K. Lefkowitz, T. W. Lovenberg, and R. Levi
Coupling of histamine H3 receptors to neuronal Na+/H+ exchange: A novel protective mechanism in myocardial ischemia
PNAS, February 15, 2001; (2001) 51599198.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
G. Drutel, N. Peitsaro, K. Karlstedt, K. Wieland, M. J. Smit, H. Timmerman, P. Panula, and R. Leurs
Identification of Rat H3 Receptor Isoforms with Different Brain Expression and Signaling Properties
Mol. Pharmacol., January 1, 2001; 59(1): 1 - 8.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. B. Silver, K. S. Poonwasi, N. Seyedi, S. J. Wilson, T. W. Lovenberg, and R. Levi
Decreased intracellular calcium mediates the histamine H3-receptor-induced attenuation of norepinephrine exocytosis from cardiac sympathetic nerve endings
PNAS, January 8, 2002; 99(1): 501 - 506.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. B. Silver, C. J. Mackins, N. C. E. Smith, I. L. Koritchneva, K. Lefkowitz, T. W. Lovenberg, and R. Levi
Coupling of histamine H3 receptors to neuronal Na+/H+ exchange: A novel protective mechanism in myocardial ischemia
PNAS, February 27, 2001; 98(5): 2855 - 2859.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.